Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.42
SNSS's Cash-to-Debt is ranked lower than
67% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. SNSS: 2.42 )
Ranked among companies with meaningful Cash-to-Debt only.
SNSS' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.69  Med: 16.85 Max: No Debt
Current: 2.42
Equity-to-Asset 0.40
SNSS's Equity-to-Asset is ranked lower than
72% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SNSS: 0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
SNSS' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.31  Med: 0.48 Max: 0.89
Current: 0.4
-3.31
0.89
Piotroski F-Score: 2
Altman Z-Score: -24.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -1404.72
SNSS's Operating Margin % is ranked lower than
81% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. SNSS: -1404.72 )
Ranked among companies with meaningful Operating Margin % only.
SNSS' s Operating Margin % Range Over the Past 10 Years
Min: -64863.64  Med: -745.14 Max: -399.36
Current: -1404.72
-64863.64
-399.36
Net Margin % -1472.55
SNSS's Net Margin % is ranked lower than
82% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. SNSS: -1472.55 )
Ranked among companies with meaningful Net Margin % only.
SNSS' s Net Margin % Range Over the Past 10 Years
Min: -74506.06  Med: -909.61 Max: -401.09
Current: -1472.55
-74506.06
-401.09
ROE % -282.38
SNSS's ROE % is ranked lower than
92% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. SNSS: -282.38 )
Ranked among companies with meaningful ROE % only.
SNSS' s ROE % Range Over the Past 10 Years
Min: -1585.52  Med: -167.56 Max: -57.33
Current: -282.38
-1585.52
-57.33
ROA % -105.56
SNSS's ROA % is ranked lower than
85% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. SNSS: -105.56 )
Ranked among companies with meaningful ROA % only.
SNSS' s ROA % Range Over the Past 10 Years
Min: -448.13  Med: -81.16 Max: -39.99
Current: -105.56
-448.13
-39.99
ROC (Joel Greenblatt) % -618344.83
SNSS's ROC (Joel Greenblatt) % is ranked lower than
99% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. SNSS: -618344.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SNSS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -618344.83  Med: -46443.7 Max: -859.84
Current: -618344.83
-618344.83
-859.84
3-Year Revenue Growth Rate -43.80
SNSS's 3-Year Revenue Growth Rate is ranked lower than
83% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. SNSS: -43.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SNSS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -90.9  Med: -43.8 Max: 385.2
Current: -43.8
-90.9
385.2
3-Year EBITDA Growth Rate -14.00
SNSS's 3-Year EBITDA Growth Rate is ranked lower than
68% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. SNSS: -14.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SNSS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -59.6  Med: -35.2 Max: 16.2
Current: -14
-59.6
16.2
3-Year EPS without NRI Growth Rate -15.10
SNSS's 3-Year EPS without NRI Growth Rate is ranked lower than
66% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. SNSS: -15.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SNSS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.4  Med: -17.9 Max: 21
Current: -15.1
-60.4
21
GuruFocus has detected 3 Warning Signs with Sunesis Pharmaceuticals Inc $SNSS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SNSS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

SNSS Guru Trades in Q2 2016

First Eagle Investment 1,500,000 sh (New)
Jim Simons 272,326 sh (+288.84%)
» More
Q3 2016

SNSS Guru Trades in Q3 2016

Jim Simons 94,581 sh (+108.38%)
First Eagle Investment 249,999 sh (unchged)
» More
Q4 2016

SNSS Guru Trades in Q4 2016

First Eagle Investment 574,999 sh (+130.00%)
Jim Simons 110,581 sh (+16.92%)
» More
Q1 2017

SNSS Guru Trades in Q1 2017

Jim Simons 111,811 sh (+1.11%)
First Eagle Investment 319,480 sh (-44.44%)
» More
» Details

Insider Trades

Latest Guru Trades with SNSS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:ARTH, NAS:NVIV, NAS:LPTX, NAS:MTP, OTCPK:CWBR, NAS:DRNA, NAS:KALV, OTCPK:BBLG, NAS:XENE, NAS:APEN, OTCPK:PMCB, NAS:ALDX, NAS:CXRX, NAS:GTXI, AMEX:NAVB, NAS:EGLT, NAS:AQB, OTCPK:HBPCF, OTCPK:ONCYF, AMEX:SYN » details
Traded in other countries:RYIP.Germany,
Headquarter Location:USA
Sunesis Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.

Sunesis Pharmaceuticals Inc was incorporated in the state of Delaware on February 10, 1998. It is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. It currently focuses on the development of vosaroxin for the treatment of acute myeloid leukemia, or AML. Vosaroxin is an anti-cancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. In October 2014, the Company announced the results of a Phase 3, multi-national, randomized, double-blind, placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML, or the VALOR trial. The VALOR trial, which enrolled 711 adult patients, was designed to evaluate the effect of vosaroxin in combination with cytarabine, commonly used chemotherapy in AML, on overall survival as compared to placebo in combination with cytarabine, and was conducted at 124 study sites in the U.S., Canada, Europe, South Korea, Australia and New Zealand. It faces competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching, developing and marketing products designed to address the treatment of cancer, including AML and ovarian cancer. In addition to regulations in the United States, the Company is subject to foreign regulations governing clinical trials and commercial sales and distribution of vosaroxin or its future drug candidates, if any.

Top Ranked Articles about Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights
Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML
Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting
Sunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Eric Bjerkholt, Executive Vice President Corporate Development and Finance and Chief Financial Officer of Sunesis, will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4th at 8:40 AM Eastern Time at The Westin Grand Central in New York City.
A live webcast of the presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks. About Sunesis Pharmaceuticals Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer. Currently, the company is focused on pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older, as well as advancing its novel kinase-inhibitor pipeline, which includes its proprietary non-covalent BTK-inhibitor, SNS-062. For additional information on Sunesis, please visit http://www.sunesis.com. SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902

Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717

Read more...
Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin

SOUTH SAN FRANCISCO, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it has submitted its responses to the European Medicine Agency (EMA) Day 180 List of Outstanding Issues issued by the Committee for Medicinal Products for Human Use (CHMP) as part of the centralized review process of the Marketing Authorization (MAA) for vosaroxin as a treatment for relapsed/refractory acute myeloid leukemia (AML) in patients aged 60 years and older.
“Our team has provided detailed answers to the EMA in response to the Day 180 List of Outstanding Issues,” said Daniel Swisher, President and Chief Executive Officer of Sunesis. “We are preparing to go before the Scientific Advisory Group’s Oncology Division (SAG-O) in April, which will assist the CHMP in its evaluation of our application. As we approach this final phase of the European approval process, anticipating a CHMP decision by mid-year, we continue to work in parallel to qualify the best pharma partner to work with us on a European market launch of vosaroxin in the second half of 2017.” About QINPREZO™ (vosaroxin) QINPREZO™ (vosaroxin) is an anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer. Preclinical data demonstrate that vosaroxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Both the U.S. Food and Drug Administration (FDA) and European Commission have granted orphan drug designation to vosaroxin for the treatment of AML. Additionally, vosaroxin has been granted fast track designation by the FDA for the potential treatment of relapsed/refractory AML in combination with cytarabine. Vosaroxin is an investigational drug that has not been approved for use in any jurisdiction. Vosaroxin’s Marketing Authorization Application for relapsed refractory AML is currently under review by the European Medicines Agency, and a regulatory decision regarding approval is expected in 2017. The trademark name QINPREZO is conditionally accepted by the FDA and the EMA as the proprietary name for the vosaroxin drug product candidate. About Sunesis Pharmaceuticals Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer. Currently, the company is focused on pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older, as well as advancing its novel kinase-inhibitor pipeline, which includes its proprietary non-covalent BTK-inhibitor, SNS-062. For additional information on Sunesis, please visit http://www.sunesis.com. SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc. This press release contains forward-looking statements, including statements related to Sunesis' corporate objectives, the regulatory development, Sunesis’ response to Day 180 List of Outstanding Issues and the anticipated timing of a CHMP decision, and potential approval of vosaroxin by the EMA, potential collaborations and ability to commercialize vosaroxin in Europe. Words such as “advancing,” “anticipate,” “expect,” "potential,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis may not be able to receive regulatory approval of vosaroxin in the U.S. or Europe, that Sunesis' development activities for vosaroxin could be otherwise halted or significantly delayed for various reasons, risks related to Sunesis' need for substantial additional funding to complete the development and commercialization of vosaroxin and other product candidates, the risk that Sunesis' clinical studies for vosaroxin or other product candidates, including its pipeline of kinase inhibitors, may not demonstrate safety or efficacy or lead to regulatory approval, the risk that data to date and trends may not be predictive of future data or results, risks related to the conduct of Sunesis' clinical trials, and risks related to Sunesis' ability to raise the capital that it believes to be accessible and is required to fully finance the development and commercialization of vosaroxin and other product candidates. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Annual Report on Form 10-K for the year ended December 31, 2016 and Sunesis' other filings with the Securities and Exchange Commission.  Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Sunesis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902

Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717

Read more...

Ratios

vs
industry
vs
history
PS Ratio 20.81
SNSS's PS Ratio is ranked lower than
66% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. SNSS: 20.81 )
Ranked among companies with meaningful PS Ratio only.
SNSS' s PS Ratio Range Over the Past 10 Years
Min: 1.71  Med: 20.34 Max: 936
Current: 20.81
1.71
936
EV-to-EBIT -1.84
SNSS's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. SNSS: -1.84 )
Ranked among companies with meaningful EV-to-EBIT only.
SNSS' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.8  Med: -2.3 Max: 1.2
Current: -1.84
-10.8
1.2
EV-to-EBITDA -1.84
SNSS's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. SNSS: -1.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNSS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.8  Med: -2.4 Max: 1.2
Current: -1.84
-10.8
1.2
Current Ratio 3.14
SNSS's Current Ratio is ranked lower than
51% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. SNSS: 3.14 )
Ranked among companies with meaningful Current Ratio only.
SNSS' s Current Ratio Range Over the Past 10 Years
Min: 0.71  Med: 2.97 Max: 12.17
Current: 3.14
0.71
12.17
Quick Ratio 3.14
SNSS's Quick Ratio is ranked higher than
51% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. SNSS: 3.14 )
Ranked among companies with meaningful Quick Ratio only.
SNSS' s Quick Ratio Range Over the Past 10 Years
Min: 0.71  Med: 2.97 Max: 12.17
Current: 3.14
0.71
12.17

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -32.20
SNSS's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. SNSS: -32.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SNSS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -197.7  Med: -32.2 Max: -6.2
Current: -32.2
-197.7
-6.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.88
SNSS's Price-to-Net-Cash is ranked higher than
68% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. SNSS: 4.88 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SNSS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.7  Med: 3.35 Max: 194.73
Current: 4.88
1.7
194.73
Price-to-Median-PS-Value 1.03
SNSS's Price-to-Median-PS-Value is ranked lower than
68% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. SNSS: 1.03 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SNSS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 0.85 Max: 46.8
Current: 1.03
0.04
46.8
Earnings Yield (Greenblatt) % -54.82
SNSS's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. SNSS: -54.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SNSS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -55  Med: 123.6 Max: 16999.7
Current: -54.82
-55
16999.7

More Statistics

Revenue (TTM) (Mil) $2.57
EPS (TTM) $ -2.19
Beta0.61
Short Percentage of Float0.70%
52-Week Range $2.73 - 6.30
Shares Outstanding (Mil)21.46

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -1.44 -1.45
EPS without NRI ($) -1.44 -1.45
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SNSS

Headlines

Articles On GuruFocus.com
Lifshitz & Miller LLP Announces Investigation of Anadarko Petroleum Corporation, DryShips Inc., Immu May 15 2017 
Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights May 08 2017 
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sunesis Pharmaceuticals, Inc. for May 02 2017 
SUNESIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50, May 02 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sunesis Pharmace May 02 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sunesis Pharmaceuti May 02 2017 
Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) f May 01 2017 
Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical St Apr 03 2017 
Sunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference Mar 28 2017 
Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Iss Mar 22 2017 

More From Other Websites
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc.... May 19 2017
The Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug May 19 2017
Lifshitz & Miller LLP Announces Investigation of Anadarko Petroleum Corporation, DryShips Inc.,... May 15 2017
Edited Transcript of SNSS earnings conference call or presentation 8-May-17 6:00pm GMT May 12 2017
ETFs with exposure to Sunesis Pharmaceuticals, Inc. : May 11, 2017 May 11 2017
Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 May 10 2017
Investor Network: Sunesis Pharmaceuticals, Inc. to Host Earnings Call May 08 2017
Sunesis reports 1Q loss May 08 2017
Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights May 08 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Sunesis... May 04 2017
INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis... May 03 2017
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals,... May 03 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Involving Possible... May 03 2017
Blog Coverage Sunesis Pharma Withdraws European Marketing Authorization Application for Vosaroxin May 03 2017
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. May 02 2017
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sunesis Pharmaceuticals, Inc. for... May 02 2017
SUNESIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding... May 02 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sunesis... May 02 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sunesis... May 02 2017
Sunesis shares drop as biotech drops leukemia drug marketing application May 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat